The introduction of anti-vascular endothelial growth factor (VEGF) therapy represents a landmark in the management of wet age-related macular degeneration (AMD). However, as a new therapy, several problems such as durability of the therapeutic effects, medication side effects, and medication selection have emerged. We should make appoint of improving the therapeutic effect and safety by realizing the limitation of the therapy, monitoring the clinical potential adverse reactions of anti-VEGF agents, and recommending individualized treatment.
Citation： 王雨生,侯慧媛. Concerns about antivascular endothelial growth factor therapy for exudative age related macular degeneration treatment. Chinese Journal of Ocular Fundus Diseases, 2010, 26(1): 6-8. doi: Copy